How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
